STOCK TITAN

Standard BioTools (LAB) 424B Filings

LAB NASDAQ

Here are the 424B prospectus supplements from Standard BioTools Inc. (LAB) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 424B covers the supplement that carries the terms of a priced offering, so if you follow LAB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LAB filings page.

Rhea-AI Summary

Standard BioTools Inc. registers for resale by certain Treeline stockholders up to 1,551,769,528 shares of common stock, based on an estimated exchange ratio of 11.7157; the shares represent approximately 59% of common stock expected to be outstanding immediately after the merger. Standard BioTools will receive no proceeds from these resales and will bear registration costs; selling holders bear any commissions or discounts.

Following the proposed all-stock merger, former Treeline stockholders are expected to own approximately 84% and former Standard BioTools stockholders approximately 16% of the combined company on a fully diluted basis. The merger is subject to stockholder approval, including for a proposed 1-for-20 to 1-for-40 reverse split and a name change to Treeline Biosciences. Separately, Element is to acquire Standard BioTools’ mass cytometry business for $5.5 million on a cash-free and debt-free basis, subject to customary adjustments, stockholder approval and merger completion. The merger is expected to be accounted for as a reverse recapitalization with Treeline as accounting acquirer.

Rhea-AI Summary

Standard BioTools Inc. (LAB) registers up to 537,687,757 shares of common stock for issuance in its proposed all-stock merger with Treeline Biosciences, Inc. and resale by certain Treeline stockholders; LAB will receive no proceeds from those resales. Merger Sub would merge into Treeline, which would survive as LAB’s wholly owned subsidiary, subject to stockholder approval of the share issuance and charter amendment. If completed, LAB will change its name to Treeline Biosciences, Inc.; a 1-for-20 to 1-for-40 reverse stock split would occur at the effective time if not effected earlier, at a final ratio the companies mutually agree.

After closing, former LAB stockholders are expected to own approximately 16% and former Treeline stockholders approximately 84% of the combined company on a fully diluted basis, subject to adjustment for closing net cash. LAB expects to declare one contingent value right per outstanding share held on the last business day before the effective time. Payments would be based on specified net proceeds over a five-year term; no payments are assured, and issuance is capped at 76,000,000 shares of combined-company common stock. The mass cytometry sale to Element requires stockholder approval and merger completion. The special meeting is scheduled for November 19, 2026.